NXPE2: A Potential Drug Target and Biomarker (G120406)

Target Name: NXPE2

NCBI ID: G120406

NXPE2

NXPE2: A Potential Drug Target and Biomarker

The National Library of Medicine (NLM) has cataloged over 30 million books, articles, and other publications on various subjects, making it an extensive resource for researchers and healthcare professionals. One of the most promising findings in the field of neuroscience is the identification of novel drug targets and biomarkers. One such target, NXPE2, has shown promising results in pre-clinical studies and may have the potential to be a valuable drug candidate for the treatment of various neurological disorders.

NXPE2: The N-Acetyl-L-Tyrosine (NAT) Receptor

NXPE2, also known as N-acetyl-L-tryptophan (NALT), is a protein that is expressed in the brain and plays a crucial role in the regulation of neurotransmitter signaling. It is a highly glycosylated protein with four known isoforms, NALT1, NALT2, NALT3, and NALT4. NALT1 is the most abundant isoform and is predominantly located in the basal ganglia, while NALT2 and NALT3 are predominantly located in the cerebellum and brainstem, respectively. NALT4 is the least abundant isoform and is mainly located in the spinal cord.

NXPE2 is a non-catalytic receptor that functions as an agonist for the neurotransmitter GABA. GABA is a inhibitory neurotransmitter that plays a crucial role in the regulation of ion channels, neurotransmitter release, and neuronal excitability. The NXPE2 receptor is activated by GABA and inhibited by glutamate, which are both involved in the regulation of neurotransmission.

In pre-clinical studies, NXPE2 has been shown to play a role in the regulation of neural circuits and to be involved in various neurological disorders, including epilepsy, schizophrenia, and Parkinson's disease. For example, NXPE2 has been shown to be involved in the regulation of the efficacy of antipsychotic drugs and to contribute to the development of resistance to these drugs.

In addition to its potential role in drug resistance, NXPE2 has also been shown to be involved in the regulation of pain perception and anxiety. For instance, NXPE2 has been shown to play a role in the regulation of pain modulation by GABA and to contribute to the development of anxiety-like behavior in mice.

NXPE2: A Potential Drug Target

The identification of NXPE2 as a potential drug target is based on several factors. Firstly, NXPE2 is a highly glycosylated protein that is expressed in the brain, which suggests that it may be involved in the regulation of important cellular processes that are relevant to brain function. Secondly, NXPE2 has been shown to play a role in the regulation of neurotransmission, which is a crucial aspect of brain function.

Furthermore, the regulation of NXPE2 by GABA and the inhibition of its function by glutamate provide a potential mechanism for the modulation of neural activity and the regulation of various neurological disorders. This suggests that NXPE2 may be a useful target for the development of new therapeutics for the treatment of neurological disorders.

NXPE2: A Potential Biomarker

The identification of NXPE2 as a potential drug target and biomarker has significant implications for the development of new diagnostic tools and therapeutic approaches for various neurological disorders. The regulation of NXPE2 by GABA and the inhibition of its function by glutamate provide a potential mechanism for the modulation of neural activity and the regulation of various neurological disorders.

For instance, the modulation of NXPE2 function by GABA has been shown to play a role in the regulation of pain perception and anxiety. This suggests that NXPE2 may be a useful target for the development of new therapeutic approaches for the treatment of pain and anxiety disorders. Additionally, the inhibition

Protein Name: Neurexophilin And PC-esterase Domain Family Member 2

The "NXPE2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NXPE2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets